Avanos Medical (NYSE:AVNS) Issues FY 2026 Earnings Guidance

Avanos Medical (NYSE:AVNS) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.900-1.100 for the period, compared to the consensus estimate of 1.030. The company issued revenue guidance of $700.0 million-$720.0 million, compared to the consensus revenue estimate of $704.7 million.

Analyst Ratings Changes

Several research firms have recently commented on AVNS. Zacks Research upgraded shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. Wall Street Zen upgraded Avanos Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Avanos Medical Stock Performance

Shares of NYSE AVNS opened at $14.35 on Thursday. The firm has a market cap of $666.31 million, a price-to-earnings ratio of -9.08 and a beta of 1.09. Avanos Medical has a 52 week low of $9.30 and a 52 week high of $16.63. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.36 and a current ratio of 2.15. The business’s 50-day simple moving average is $12.95 and its 200-day simple moving average is $12.06.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.24 by $0.05. Avanos Medical had a negative net margin of 10.40% and a positive return on equity of 5.47%. The business had revenue of $180.90 million for the quarter, compared to analysts’ expectations of $174.70 million. During the same period in the previous year, the firm posted $0.43 EPS. The firm’s revenue was up .7% compared to the same quarter last year. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. As a group, equities research analysts expect that Avanos Medical will post 1.32 earnings per share for the current fiscal year.

Institutional Trading of Avanos Medical

Several hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC grew its holdings in Avanos Medical by 312.4% in the 3rd quarter. Millennium Management LLC now owns 896,242 shares of the company’s stock valued at $10,361,000 after buying an additional 678,898 shares in the last quarter. Armistice Capital LLC grew its stake in shares of Avanos Medical by 22.8% in the third quarter. Armistice Capital LLC now owns 2,500,000 shares of the company’s stock valued at $28,900,000 after acquiring an additional 464,000 shares in the last quarter. Ameriprise Financial Inc. increased its position in Avanos Medical by 356.6% during the third quarter. Ameriprise Financial Inc. now owns 591,181 shares of the company’s stock worth $6,834,000 after acquiring an additional 461,706 shares during the period. Citadel Advisors LLC raised its stake in Avanos Medical by 212.0% in the 3rd quarter. Citadel Advisors LLC now owns 574,104 shares of the company’s stock worth $6,637,000 after purchasing an additional 390,082 shares in the last quarter. Finally, AQR Capital Management LLC boosted its holdings in Avanos Medical by 190.4% in the 2nd quarter. AQR Capital Management LLC now owns 560,052 shares of the company’s stock valued at $6,855,000 after purchasing an additional 367,188 shares during the period. 95.17% of the stock is owned by institutional investors and hedge funds.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.